Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma

NCT07657494 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Aggressive Lymphoma

Interventions

DRUG: Al18F-NOTA-FAPI
DRUG: Al18F-NOTA-grazytracer/68Ga-grazytracer

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences